The Connecticut State Legislature has introduced Senate Bill 11, a significant piece of legislation aimed at allowing the importation of prescription drugs from Canada. Introduced on April 2, 2025, the bill seeks to address rising prescription drug costs by enabling state-licensed wholesalers to import certain medications from participating Canadian suppliers.

The main provisions of Senate Bill 11 stipulate that imported drugs must meet federal Food and Drug Administration (FDA) standards for safety and effectiveness, and their importation must not violate federal patent laws. Notably, the bill excludes controlled substances, biological products, and certain types of infused or injected drugs from being imported under this program. If enacted, the bill would allow participating wholesalers to distribute these imported drugs to pharmacies and qualifying laboratories starting October 1, 2027.

The bill has sparked considerable debate among lawmakers and stakeholders. Proponents argue that it could significantly lower drug prices for consumers in Connecticut, providing relief to those struggling with high medication costs. They emphasize the potential for increased competition in the pharmaceutical market as a key benefit. However, opponents raise concerns about the safety and reliability of imported drugs, questioning whether Canadian suppliers can consistently meet U.S. standards. Additionally, there are fears that the bill could conflict with federal regulations, potentially leading to legal challenges.

The economic implications of Senate Bill 11 are noteworthy, as it could reshape the pharmaceutical landscape in Connecticut. By facilitating access to more affordable medications, the bill may alleviate financial burdens on residents and potentially reduce healthcare costs statewide. However, the political ramifications could be significant, as the bill's success hinges on navigating complex federal laws and regulations regarding drug importation.

As the legislative process unfolds, experts suggest that the outcome of Senate Bill 11 could set a precedent for other states considering similar measures. The bill's future will depend on ongoing discussions, potential amendments, and the response from federal authorities regarding drug importation policies.